Pack size: Box of 10 Tablets | Price is for the whole Box
Generic: Abemaciclib
Form: Tablet 150mg
Breast Cancer
May take with or without food Instruct patient to take dose at approximately the same time each day
Breast Cancer Indicated for HR+/HER2- advanced or metastatic breast cancer with disease progression following endocrine therapy as either monotherapy or in combination with fulvestrant Also, indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer Monotherapy 200 mg PO BID Continue until disease progression or unacceptable toxicity Combination therapy With aromatase inhibitor Abemaciclib: 150 mg PO BID PLUS Aromatase inhibitor: See Prescribing Information Continue until disease progression or unacceptable toxicity With fulvestrant Abemaciclib: 150 mg PO BID PLUS Fulvestrant: 500 mg IM on Days 1, 15, and 29, and then once monthly thereafter Continue until disease progression or unacceptable toxicity Hepatic impairment Mild or moderate (Child-Pugh A or B): No dose adjustment required Severe (Child-Pugh C): Reduce dosing frequency to once daily
Renal impairment Mild or moderate (CrCl 30-89 mL/min): No dose adjustment required Severe, ESRD, or dialysis: Not studied
Inhibits cyclin-dependent kinases (CDKs) 4 and 6 These kinases are activated upon binding to D cyclins and play a crucial role in signaling pathways, which lead to cell cycle progression and cellular proliferation In ER-positive breast cancer cells, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation
$4a
No review given yet!
Fast Delivery all across the country
Safe Payment
7 Days Return Policy
100% Authentic Products
You need to Sign in to view this feature
This address will be removed from this list
english
